Brief: Editas Medicine To Host Virtual Event To Discuss Edit-301 Clinical Data For Severe Sickle Cell Disease Trial
06/06/2023 13:57
June 6 (Reuters) - Editas Medicine Inc EDIT.O :
* EDITAS MEDICINE TO HOST VIRTUAL EVENT TO DISCUSS EDIT-301
CLINICAL DATA FROM THE RUBY TRIAL FOR SEVERE SICKLE CELL DISEASE
AND THE EDITHAL TRIAL FOR TRANSFUSION-DEPENDENT BETA THALASSEMIA
Source text for Eikon: ID:nGNX8dkhl9
Further company coverage: EDIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Editas Medicine
See all newsEditas Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Editas Medicine, Inc. expected to post a loss of 27 cents a share - Earnings Preview
Editas Medicine Q2 net loss narrows and beats estimates
Brief: Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 Million
Editas Medicine down after $125 mln stock-and-warrants offering